Epistem Regulatory News (EHP)

Epistem Holdings Plc ("Epistem" or the "Company")

Directors' Shareholdings

Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009.

As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors have each increased their beneficial interest in the Company by 198 ordinary shares of 1.5p each. These shares were acquired on 31 January 2011 and 1 March 2011 at prices of 388p and 380p respectively.

The current beneficial interests of the executive Directors are set out below:

Matthew Walls                             7,984                                   (0.10%)

Dr Catherine Booth                  982,339                                  (12.38%)

Dr Ged Brady                              2,339                                   (0.03%)

Dr Jeffrey Moore                        16,839                                   (0.21%)          

John Rylands                            192,237                                   (2.42%)

For further details please contact:

Epistem Plc

Matthew Walls, CEO                                                   +44 161 606 7258

John Rylands, Finance Director                                     +44 161 606 7244

Peel Hunt LLP

James Steel / Vijay Barathan                                         +44 20 7418 8900